Experts question reliance on monkeypox vax with little data, short supply

The Bavarian Nordic shot has not undergone clinical trials to evaluate the vaccine's ability to prevent monkeypox in humans, though initial studies suggest it will provide some protection

A reliance on vaccines in short supply and questions over their best use are hampering efforts to curb the global spread of monkeypox which has hit dozens of countries for the first time, health officials say.
 

There are just 1.5 million vials of Bavarian Nordic's monkeypox vaccine either administered or currently available in the ten worst-affected countries, which account for nearly 90% of all cases. The vast majority of doses are in the United States. The figures are based on a Reuters tally of government statements, and highlight the extent of the global supply gap for the first time.
 

The